natgillin/translations-raw huggingface dataset:
A process for preparing a purified conjugate in a solution, wherein the conjugate comprises an effector or a reporter molecule linked to a cell binding agent, the process comprising the steps of: (a) contacting the effector or the reporter molecule with a bifunctional linker reagent to covalently attach the linker to the effector or the reporter molecule and thereby prepare an unpurified first mixture comprising the effector or the reporter molecule having linkers bound thereto, (b) conjugating a cell binding agent to the effector or the reporter molecule having linkers bound thereto by reacting the unpurified first mixture with the cell binding agent to prepare a second mixture, and (c) subjecting the second mixture to a tangential flow filtration, dialysis, gel filtration, adsorptive chromatography, selective precipitation or a combination thereof to thereby prepare the purified conjugate. 
PATENTNI ZAHTJEVI NR wam Postupak za pripravu pročišćenog konjugata u otopini, naznačen time što konjugat sadrži majtanzinoid koji sadrži tiolnu skupinu vezanu na protutijelo, te postupak obuhvaća korake: (a) dovođenje u kontakt majtanzinoida s bifunkcionalnim veznim reagensom za kovalentno vezanje poveznice na majtanzinoid i na taj način pripravljanje nepročišćene prve smjese koja sadrži majtanzinoid s vezanim poveznicama, (b) konjugiranje protutijela na majtanzinoid s vezanim poveznicama reakcijom nepročišćene prve smjese s protutijelom da se dobije druga smjesa, te (c) podvrgavanje druge smjese tangencijalnoj protočnoj filtraciji, dijalizi, gel filtraciji, adsorpcijskoj kromatografiji, selektivnom taloženju ili njihovoj kombinaciji, te se na taj način pripravlja pročišćeni konjugat.
In particular, the single phase power network 10 is connected via two fuses 11 to conductors 12 and 14, which reach the separable contacts 22a, 22b of the relay 20; when the coil 21 of relay 20 is energized, said contacts 22a, 22b contact two terminals 24a, 24b, from which two conductors 12a, 12b are routed and connected to the terminals of the hair-dryer 16. 
Potanko, jednofazna mreža 10 je priključena preko dva osigurača 11 na vodiče 12 i 14 koji su spojeni na odvojive kontakte 22a i 22 b releja 20; kad je zavojnica 21 releja 20 pod naponom, spomenuti kontakti 22a, 22b su u kontaktu s priključcima 24a, 24b od kojih su dva vodiča 12a, 12 b provedena i spojena na priključke sušila za kosu.
A compound of formula (I) according to any one of claims 1 to 9 for use in reducing serum uric acid levels in a human, treating hyperuricemia in a human with gout, treating hyperuricemia in a human, treating gout in a human, treating or preventing a condition characterized by abnormal tissue or organ levels of uric acid in an individual, and optionally, wherein the compound is used in combination with a second agent effective for the treatment of the gout. 
Spoj formule (D sukladno bilo kojem od patentnih zahtjeva 1 do 9 za uporabu u smanjenju razine mokraćne kiseline u serumu kod čovjeka, liječenju hiperurikemije kod čovjeka s gihtom, liječenje hiperurikemije kod čovjeka, liječenje gihta kod čovjeka, liječenje ili prevenciju stanja naznačenog abnormalnim razinama mokraćne kiseline u tkivu ili organu kod pojedinca, i izborno, gdje je spoj korišten u kombinaciji s drugim učinkovitim sredstvom u liječenje gihta.
At first, the device 30 has an equipment 60 for the coarse planing, in which the surfaces of board-like, plane pieces of wood are coarsely planned, for example by means of a planer or the like. 
Prvo, uređaj 30 ima opremu 60 za grubo ravnanje, u kojoj se grubo izravnaju površine ravnog komada od drva koji ima oblik ploče, na primjer, pomoću naprave za ravnanje ili nečega tome sličnog.
Two values of a may then be calculated by the relationships: 
Dvije vrijednosti za a mogu se tada izračunati pomoću relacije:
acceptable conforming A pharmaceutical composition comprising (1) rebamipide, (2) an amino sugar, and (3) a buffer agent, which has no inorganic cation. 
Farmaceutski pripravak naznačen time da sadrži (1) rebamipid, (2) amino šećer, te (3) pufersko sredstvo, koje nema anorganski kation.
The security element according to any one of the preceding claims, characterized in that the magnetic materials (4, 5) have different coercivity values, wherein their remanence values are changed by setting different thicknesses of the materials (4, 5). 
Sigurnosni element prema bilo kojem od prethodnih zahtjeva, naznačen time što magnetski materijali (4, 5) imaju različite vrijednosti sile, pri čemu su njihove vrijednosti remanencije (otpornosti) promijenjene podešavanjem različite debljine materijala (4, 5).
adding not more than 4% by weight, relative to the total of the mass, of at least one modifying agent to melted polyethylene terephthalate, said at least one modifying agent containing silicon and being suitable to connect together low molecular fragments of polyethylene terephthalate PET; 
- u prvom koraku istaljenom PET-u doda ne više od 4% težine, u odnosu na cjelokupnu masu, barem jednog agensa za modificiranje koji sadrži silikon 1 koji može zajedno spojiti molekulske fragmente PET-a niske molekulske mase, te se tada miješa kako bi reagirao,
The compound of claim 1, wherein (i) R1 and R2 are each methyl and R3 is -COOH, (ii) R1 and R2 together with the carbon to which they are both attached form a cyclopropane ring and R3 is -COOH, or (iii) R1 and R2 are both H and R3 is -COOH. 
Spoj prema zahtjevu 1, naznačen time što R1 i R2 zajedno s ugljikom na koji su vezani tvore ciklopropanski prsten i R3 je -COOH.
The pharmaceutical composition of claim 14 wherein the amine-containing monomer is a linear amine possessing at least two reactive amine moieties to participate in the substitution polymerization reaction. 
Farmaceutski pripravak prema patentnom zahtjevu 14, gdje je monomer koji sadrži amin linearni amin koji posjeduje najmanje dva reaktivna aminska ostatka koji sudjeluju u reakciji supstitucijske polimerizacije.
After inhalation, the mouthpiece cover (2) is moved from the second position to the first position wherein the mouthpiece (14) is completely covered. 
Uređaj za inhaliranje prema zahtjevu 8, naznačen time da je oblik završetka pogonskog zupčanika (12a) koji je spojen na poklopac nastavka za usta (2) trapezoidan.
the polynucleotides of the library are operably linked to a display protein encoding sequence and introduced into an expression vector for display and expressed as a fusion protein; or 
polinukleotidi biblioteke operativno vezani za prikazanu sekvencu kodiranja proteina i uvedeni su u ekspresijski vektor za prikaz, i izraženi kao fuzioni protein; ili
q is 0 or an integer from 1 to 5. 
qje 0 ili cijeli broj od I do 5.
is an aromatic group, methyl or trihalogenated methyl; X is a leaving group selected from the group consisting of halogens, esters, sulfonates and phosphates; 
P je zaštitna skupina; X je izlazna skupina, koju se bira iz skupine koju čine Cl, Br, I i heterociklički prsteni;
and wherein the fraction of viable cells in the tissue-engineered product is directly proportional to the difference between the level of cell death-stable enzyme activity in the portion of the cell culture medium containing cells and conditioned medium of the tissue-engineered product and the level of cell death-stable enzyme activity in the portion of the cell culture conditioned medium not containing cells of the tissue-engineered product. 
HR P20140825 T1 pri čemu i fje udio ukupnog uzorka kondicioniranog medija koji je prisutan u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice iz populacije stanica; i pri čemu kada je omjer postotka stanica prema postotku kondicioniranog medija stanične kulture u dijelu uzorka odstupa od 1:1, udio vijabilnih stanica u produktu preinačenog-tkiva se može izračunati prema formuli:
Lethargic 30 % weight loss No recovery 2 
gubitak 30% težine bez oporavka letargija 2
The IL-2 in PROLEUKIN™ is also designed to have two internal cysteine residues, rather than the natural three. 
IL-2 u PROLEUKIN-u"M" je također zamišljen da ima dva interna cisteinska ostatka, prije nego prirodnih tri.
Identity document according to Claim 10, wherein said pattern comprises a face. Identity document according to one of the preceding claims, wherein said reinforcement layer comprises tissue reinforcements provided at a distance from each other, said perforation being provided between said tissue reinforcements. 
Osobna isprava u skladu s jednim od prethodnih patentnih zahtjeva, naznačena time što navedeni sloj za pojačanje ima pojačanja od tkanog materijala, koja pojačanja su postavljena na razmaku jedno od drugoga, pri čemu je perforacija postavljena između navedenih pojačanja od tkanog materijala.
3-Bromo- N -hydroxypyridine-2-sulfonamide (33) 
(33) Država ili organizacija podnošenja prve prijave:
Ulipristal acetate, or a metabolite thereof selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in treating or preventing leiomyomatosis or metastatic leiomyoma according to anyone of claims 1 to 4 wherein it is to be administered in form of an oral dosage during a period of about 2 to about 4 months. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku oralne doze kroz period od oko 2 do oko 4 mjeseca.
R represents any one of formulae (I) to (VIII): 
R predstavlja bilo koju formulu od (I) do (VIII): 6 h
A procedure for assembling and pressure testing the gas valve unit for a gas consumer in a marine vessel according to an embodiment of the invention comprises 
Postupak za sastavljanje 1 tlačno ispitivanje jedinice plinskog ventila (10) za potrošača plina u morskom plovilu, naznačen time što postupak obuhvaća:
Female rats were used in this paradigm as it has previously been found that males to be less sensitive to the deficit induced by PCP (Grayson and Neill, idem .) and females show more robust performance following increasing inter-trial intervals compared with male rats (Sutcliffe et al, idem). Methods The Novel Object Recognition Paradigm: 
U ovom obrascu su korištene ženke štakora jer je ranije bilo pronađeno da su mužjaci manje osjetljivi na deficit potaknut s PCP (Grayson i Neill, idem.) i da ženke pokazuju znatno robusnije karakteristike nakon povećanja razdoblja između ispitivanja u usporedbi s mužjacima štakora (Sutcliffe 1 sur., idem).
Here, Formula 35 (0.2 g, 0.246 mmol) and DMAP (0.5 g, 4.1 mmol) were weighed into a pear shaped flame-dried flask purged with N2. 
Ovdje su formula 35 (0.2 g, 0.246 mmol) i DMAP (0.5 g, 4.1 mmol) bili odvagnuti u kruškastu tikvicu za sušenje na plamenu pročišćenu s N,.
A well apparatus as claimed in claim 13, wherein the packer is provided in use in an expanded configuration and acts as a permanent barrier to resist fluid flow. 
Bunarska aparatura, u skladu s bilo kojim prethodnim patentnim zahtjevom 10-12, naznačeno time, da je paker (16) osiguran u uporabi u proširenoj konfiguraciji I dijela kao trajna barijera koja onemogućuje protok tekućine.
providing a first feed stream comprising a liquid composition into the granulation zone, the liquid composition being applied onto or over the moving particles in the granulation zone; 
osiguravanje prvog dovodnog toka (2) koji sadrži tekući pripravak u granulacijskoj zoni, tekući pripravak nanosi se na ili preko pokretnih čestica u granulacijskoj zoni;
The dietary supplement of claim 1, wherein the mineral salt (h) is selected from the group consisting of disodium citrate, monopotassium phosphate, calcium lactate and magnesium taurate. 
Dodatak prehrani u skladu s patentnim zahtjevom 1, naznačen time što se mineralnu sol (h) bira iz skupine koju čine: dinatrijev citrat, monokalijev fosfat, kalcijev laktat i magnezijev taurat.
The process according to claim 1, wherein the conversion of the compound of formula (V) into the compound of formula (I) is carried out in dimethylformamide, dioxane, tetrahydrofuran or toluene. 
Postupak za industrijsku sintezu spoja formule (1) u skladu s patentnim zahtjevom 1, naznačen time, da se pretvaranje spoja formule (V) u spoj formule (I) izvodi u dimetilformamidu, dioksanu, tetrahidrofuranu ili tolucnu.
In a preferred embodiment the first and second adhesive portions together form a strip of adhesive extending along the first surface perpendicular to the first fold. 
Ubrus u skladu s patentnim zahtjevom 1, pri čemu navedeni prvi i drugi prianjajući dijelovi zajedno oblikuju traku prianjajućeg produljenja duž navedene prve površine paralelno s navedenim prvim naborom
A2A receptors contribute to control of motor behaviour by modulating the neurotransmission of GABA, dopamine, acetylcholine and glutamate in various ways. 
A2,receptori doprinose kontroli motoričkih pokreta moduliranjem neurotransmisije od GABA-e, dopamina, acetilkolina i glutamata na različite načine.
in the presence of a coupling reagent with a compound of formula 9: to yield the compound of formula 10: 
(D, u nazočnosti reagensa za spajanje kako bi se dobio spoj formule 10: ze ES |
The binder total maximum weight is around 20%. 
Ukupna masa veziva kreće se oko 20%.
Hc is selected from the group of 3- or 4-piperidinyl and 3- pyrrolidinyl; 
Hc je odabran iz skupine od sljedećih: 3- ili 4-piperidinil i 3-pirolidinil;
is selected from the group consisting of: C1-6 alkyl substituted with 1-3 R3a,-(CH2)n-C3-10 carbocycle substituted with 0-3 R3a or -(CH2)n-5-10 membered heterocycle containing carbon atoms and 1-4 heteroatoms selected from the group consisting of N, NR7, O, and S(O)p; wherein said heterocycle is substituted with 0-3 R3a; 
je odabran iz grupe koja se sastoji od: C1-6 alkil supstituiran sa 1-3 R3a, -(CH2)n-C3-10 karbocikl supstituiran sa 0-3 R3a ili -(CH2)n-5-10 članim heterociklom koji sadrži ugljikove atome i 1-4 heteroatoma odabranih iz grupe koja se sastoji od N, NR7, O, i S(O)p; gdje je navedeni heterocikl supstituiran sa 0-3 R3a;
at least 45% of the cells in the population express detectable levels of CD178 (FAS ligand), 
najmanje 45 % stanica u populaciji na svojoj površini izražava uočljive razine CD178 (FAS ligand),
The compound of any of the preceding claims, further comprising an additional peptide component that extends the in vivo retention of the compound; optionally wherein the additional peptide component is an albumin binding peptide; wherein the compound optionally comprises SEQ ID NO:39. 
Spoj prema zahtjevu 9, 10 ili 11, dalje sadrži dodatnu peptidnu komponentu koja produžuje in vivo retenciju spoja; po izboru je dodatna peptidna komponenta peptid koji veže albumin; po izboru sadrži SEQ ID NO:39.
Process for the fabrication of glass containers provided with an internally threaded neck comprising the steps of: 
Postupak proizvodnje staklenih spremnika čije grlo ima unutrašnji navoj, naznačen time što se sastoji u koracima:
a double-stranded self-complementary AAV9 vector, or a pseudotyped AAV vector comprising a double-stranded self-complementary AAV genome derived from an AAV serotype different from the AAV9 serotype and a capsid derived from an AAV9 capsid. 
- < dvolančani samokomplementarni AAV9 vektor, ili - - pseudotipizirani AAV vektor koji sadrži dvolančani samokomplementarni AAV genom deriviran iz AAV serotipa različitog od AA V9 serotipa i kapsidu deriviranu iz AAV9 kapside.
Within the capsule 1 ingredients 3 are contained, wherein the ingredients 3 are selected such that a beverage can be produced when having a liquid entering the capsule in the region of the top wall 17 of the capsule 1 and then interact which such ingredients 3. 
Unutar čahure 1 sadržani su sastojci 3, pri čemu su sastojci odabrani tako da se napitak može pripremiti na takav način da tekućina uđe u čahuru u predjelu gornje stijenke 17 čahure, i tada se pomiješa s takvim sastojcima 3.
The system (100, 200) of claim 1 further comprising a cylindrical shell or liner positioned within the central compression chamber (20) for fast liner compression. 
Sustav (100, 200) prema zahtjevu 1, naznačen time, da nadalje obuhvaća cilindričnu ljusku ili blazinicu pozicioniranu unutar centralne kompresijske komore (20) za brzo komprimiranje obloge.
wherein R1 is alkyl of up to about 8 carbon atoms, and R2 is hydrogen, methyl or ethyl, and X constitutes about 10 to 40 weight percent of terpolymer E/X/Y; 
CHs=€-C-0-R! gdje je R' alkil s do 8 atoma ugljika, a R? je vodik, metil ili etil, gdje X čini 10 do 40 posto, težinski, terpolimera E/X/Y;
to form a compound of Formula I, or salt thereof. wherein X1 is chloro, bromo, or iodo. 
NC Py NSA NHo II da se dobije spoj s formulom I, ili njegova sol; i
The method according to claim 7, wherein the composition contains at least 0.3%, of a fructosazine selected from the group consisting of 2,5-deoxyfructosazine, 2,6-deoxyfructosazine, 2,5-fructosazine, 2,6-fructosazine and combinations thereof, by weight of dry matter. 
Postupak prema zahtjevu 16-19, naznačen time, što pripravak sadržava najmanje 0,1%, poželjno najmanje 0,3%, fruktozazina odabranog iz skupine koju sačinjavaju 2,5-deoksifruktozazin, 2,6-deoksifruktozazin, 2,5-fruktozazin, 2,6-fruktozazin i njihove kombinacije, po masi suhe tvari.
The liquefied gas treatment system according to claim 2, wherein a liquid component of the BOG, which is decompressed to a gas-liquid mixed state while passing through the decompressing means, is returned to the cargo tank. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se treću struju, dekomprimiranu u plinsko-tekuće miješano stanje, vraća u spremnik za teret (11).
The method according to claim 28 wherein the method of contacting by inhalation is via administration of the compound from a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler. 
Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se primjena provodi putem dozatora za medikament koji se bira između inhalatora sa spremnikom suhog praha, višedoznog inhalatora sa suhim prahom ili inhalatora za odmjerene doze.
Thus, one preferred group of the compounds of formula I consists of the (lS)-enantiomers and the racemic mixtures of (lS)- and (lR)-enantiomers of said compounds. 
Tako se jedna poželjna skupina spoja formule I. sastoji od (1S)-enantiomera i racemskih smjesa (1S)- 1 (1R)-enantiomera spomenutih spojeva.
Also included within the definition of (C1-6) acyl and (C1-15) acyl are acyl groups derived from dicarboxylic acids like hemi-maloyl, hemi-succinoyl and hemi-glutaroyl. 
U definiciju (C,.6) acila i (Ci.1s) acila također ulaze i acilne skupine koje se izvodi iz dikarboksilnih kiselina, poput hemimaloila, hemisukcinoila i hemiglutaroila.
A process according to claims 1, wherein the salt formation is carried out with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-a-methyl-benzylamine or N-methyl-D-glucosamine in a neutral organic solvent, wherein said neutral organic solvent is acetonitrile, ethyl-acetate, ethanol or tetrahydrofuran. 
etanolaminom, magnezij-sulfatom, L-lizinom, benzilaminom, L(-)-a-metil-benzilaminom ili N-metil-D-glukozaminom u neutralnom organskom otapalu, pri čemu navedeno neutralno organsko otapalo je acetonitril, etilacetat, etanol ili tetrahidrofuran. 3.
The method of claim 3, wherein the acid treatment is performed utilizing an acid such as sulfuric acid, acetic acid, hydrochloric acid or phosphate acid, or any combination thereof, to adjust the reaction system to pH 3-5, at the temperature of 60-100°C, such as 80-100°C. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time da se obrada kiselinom provodi korištenjem kiseline za podešavanje reakcijskog sustava na pH vrijednost od 3 do 5 kod temperature od 60 do 100°C.
The compound as recited in Claim 1, wherein said muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, Becker muscular dystrophy, limb girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. 
VBP6 VBPI5 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedena mišićna distrofija izabrana iz grupe koja sadrži Duchenne mišićnu distrofiju, mišićnu distrofiju donjih udova, kongentialnu mišićnu distrofiju, facioskapulohumeralnu mišićnu distrofiju, miotoničnu mišićnu distrofiju, okulofaringealnu mišićnu distrofiju, distalnu mišićnu distrofiju i Emery-Dreifuss mišićnu distrofiju.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound cyprodinil. 
UA naznačen time da je R, difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj biksafen.
3-(2,2,2-Trimethylhydrazinium)propionate salt selected from the group consisting of dihydrogen phosphate and hydrogen fumarate for use in the treatment of myocardial infarction. 
3-(2,2,2-trimetilhidrazinij) sol na bazi propionata koja je izabrana iz skupine koja se sastoji od dihidrogen fosfata i hidrogen fumarata za uporabu u liječenju miokardijalno infarkcije.
The pharmaceutical composition of any one of claims 1-5 characterized in that 1.0% or less of the of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or of the pharmaceutically acceptable salt thereof degrades upon exposure to a 0.15% H2O2 solution for 40 minutes. 
Postupak za validaciju šarže N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamida ili njegove soli za distribuciju, naznačen time, da obuhvaća: podvrgavanje uzorka šarže ispitivanju stabilnosti;
The pest control device according to claim 9, wherein the acidity regulator consists of calcium lactate and citric acid. 
Uređaj za suzbijanje štetočina prema patentnom zahtjevu 4, naznačen time da se regulator kiseline sastoji od mliječne kiseline 1 limunske kiseline.
An antibody or fragment thereof which binds human a-synuclein protofibrils having a molecular weight in a range of from 1000 to 5000 kDa, wherein binding of the antibody or fragment to each of a-synuclein monomers and B-synuclein monomers is at least 100 times less than binding of the antibody or fragment to human a-synuclein protofibrils, the antibody or fragment having three variable heavy (VH) CDR sequences (VH-CDR-1, VH-CDR-2, and VH-CDR-3) and three variable light (VL) CDR sequences (VL-CDR-1, VL-CDR-2, and VL-CDR-3), and wherein the the antibody or fragment thereof has a CDR sequence combination selected from the following combinations: 
Protutijelo, ili njegov fragment, naznačeno time što se veže na ljudski a-sinukleinski protofibrili molekulske težine u rasponu od 1000 do 5000 kDa, gdje vezanje protutijela, ili fragmenta, na svaki od a-sinukleinskih monomera i B-sinukleinskih monomera je najmanje 100 puta slabije od vezanja protutijela, ili fragmenta, na ljudske a-sinukleinske protofibrile, gdje protutijelo, ili fragment, ima tri varijabilna teška (VH) CDR slijeda (VH-CDR-1, VH-CDR-2, te VH-CDR-3) i tri varijabilna laka (VL) CDR slijeda (VL-CDR-1, VL-CDR-2, te VL-CDR-3), te gdje protutijelo, ili njegov fragment, ima kombinacija CDR sljedova koju se bira između sljedećih kombinacija:
For example, as depicted in Figure 2, rapamycin (II) can be reacted with p-hitrophenyl chloroformate to yield an activated rapamycin (III). 
Na primjer, kako je prikazano na slici 2, rapamicin (II) može reagirati s p-nitrofenil-kloroformijatom da bi dao aktivirani rapamicin (III).